Neurobehavioral, reflexological and physical development of wistar rat offspring exposed to ayahuasca during pregnancy and lactation

Revista Brasileira de Farmacognosia

Volumn 21, Issue 6, 2011, Pages 1065-1076

  de Oliveira, Carolina Dizioli Rodrigues ^a   Moreira, Camila Queiroz ^a   Spinosa, Helenice de Souza ^a   Yonamine, Mauricio ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Ayahuasca; Neurobehavioral changes; Pregnancy; Rat offspring

Indexed keywords

MONOAMINE; PENTETRAZOLE; PLANT EXTRACT;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AYAHUASCA; BEVERAGE; COGNITION; CONTROLLED STUDY; FEMALE; FORCED SWIMMING TEST; LACTATION; LATENT PERIOD; MALE; NONHUMAN; PHYSICAL DEVELOPMENT; PREGNANCY; PRENATAL EXPOSURE; PROGENY; RAT; REFLEXOLOGY; SOCIAL INTERACTION;

EID: 80054868857     PISSN: 0102695X     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0102-695X2011005000170     Document Type: Article

References (42)

1. Bagdy G, Kecskemeti V, Riba P, Jakus R 2007. Serotonin and epilepsy. J Neurochem 100: 857-873.
2. Belzung C 1999. Measuring exploratory behavior. In: Crusio WE, Gerlai RT. Handbook of molecular genetic techniques for brain and behavior research - Techniques in the behavioral and neural sciences. Amsterdam: Elsivier Science p. 739-749.
3. Borsini F 1995. Role of the serotonergic system in the forced swimming test. Neurosci Biobehav R 19: 377-395.
4. Calabrese EJ 2008. An assessment of anxiolytic drug screening tests: Hormetic dose responses predominate. Crit Rev Toxicol 38: 489-542.
5. Callaway JC 2005. Fast and slow metabolizers of Hoasca. J Psychoactive Drugs 37: 157-161.
6. Callaway JC, McKenna DJ, Grob CS, Brito GS, Raymon LP, Poland RE, Andrade EN, Andrade EO, Mash DC 1999. Pharmacokinetics of hoasca alkaloids in healthy humans. J Ethnopharmacol 65: 243-256.
7. Cannizzaro C, Plescia F, Gagliano M, Cannizzaro G, Mantia G, LaBarbera M, Provenzano G, Cannizzaro E 2008. Perinatal exposure to 5-metoxytryptamine, behaviouralstress reactivity and functional response of 5-HT1A receptors in the adolescent rat. Behav Brain Res 186: 98-106.
8. Carlini EA 1973. Farmacologia prática sem aparelhagem. São Paulo: Editora Sarvier.
9. Carlini EA 2003. Plants and the central nervous system. Pharmacol Biochem Be 75: 501-512.
10. Castagne V, Porsolt RD, Moser P 2009. Use of latency to immobility improves detection of antidepressant-like activity in the behavioral despair test in the mouse. Eur J Pharmacol 616: 128-133.
11. Cheeta S, Kenny PJ, File SE 2000. Hippocampal and septal injections of nicotine and 8-OH-DPAT distinguish among different animal tests of anxiety. Prog Neuropsychopharmacol Biol Psychiatry 24: 1053-1067.
12. Conselho Nacional Antidrogas 2004. Resolução no. 4. Diario Oficial da Uniao (DOU) da República Federativa do Brasil.
13. Dazzi L, Serra M, Porceddu ML, Sanna A, Chessa MF, Biggio G 1997. Enhancement of basal and pentylenetetrazol (PTZ)-stimulated dopamine release in the brain of freely moving rats by ptz-induced kindling. Synapse 26: 351-358.
14. Farrar HC, Blumer JL 1991. Fetal effects of maternal drug exposure. Annu Rev Pharmacol 31: 525-547.
15. Felicio LF, Florio JC, Sider LH, Cruz-Casallas PE, Bridges RS 1996. Reproductive experience increases striatal and hypothalamic dopamine levels in pregnant rats. Brain Res Bull 40: 253-256.
16. File SE, Pellow S 1985. The effects of triazolobenzodiazepines in 2 animal tests of anxiety and in the holeboard. Brit J Pharmacol 86: 729-735.
17. File SE, Zangrossi H, Andrews N 1993. Social-interaction and elevated plus-maze tests - changes in release and uptake of 5-HT and GABA. Neuropharmacology 32: 217-221.
18. Gable RS 2007. Risk assessment of ritual use of oral dimethyltryptamine (DMT) and harmala alkaloids. Addiction 102: 24-34.
19. Grob CS, McKenna DJ, Callaway JC, Brito GS, Neves ES, Oberlaender G, Saide OL, Labigalini E, Tacla C, Miranda CT, Strassman RJ, Boone KB 1996. Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. J Nerv Ment Dis 184: 86-94.
20. Guideline for care and use of laboratory animals 1996. Institute of Laboratory Animal Research. Comission on Life Sciences National Research Council.
21. Halpern JH, Sherwood AR, Passie T, Blackwell KC, Ruttenber AJ 2008. Evidence of health and safety in American members of a religion who use a hallucinogenic sacrament. Med Sci Monitor 14: 15-22.
22. Holson JF, Nemec MD, Stump DG, Kaufman LE, Lindstrom P, Varsho BJ 2006. Significance, reliability, and interpretation of developmental and reproductive toxicity study findings. In: Hood RD. Developmental and reproductive toxicology - A Practical approach. 2 ed. Boca Raton: Taylor & Francis Group; p. 329-424.
23. Keiser MJ, Setola V, Irwin JJ, Laggner C, Abbas AI, Hufeisen SJ, Jensen NH, Kuijer MB, Matos RC, Tran TB, Whaley R, Glennon RA, Hert J, Thomas KL, Edwards DD, Shoichet BK, Roth BL 2009. Predicting new molecular targets for known drugs. Nature 462: 175-181.
24. Lauder JM, Liu JP, Grayson DR 2000. In utero exposure to serotonergic drugs alters neonatal expression of 5-HT1A receptor transcripts: a quantitative RT-PCR study. Int J Dev Neurosci 18: 171-176.
25. Lauder JM, Tamir H, Sadler TW 1998. Serotonin and morphogenesis. 1. Sites of serotonin uptake and serotonin binding-protein immunoreactivity in the midgestation mouse embryo. Development 102: 709-720.
26. Lazarini CA, Florio JC, Lemonica IP, Bernardi MM 2001. Effects of prenatal exposure to deltamethrin on forced swimming behavior, motor activity, and striatal dopamine levels in male and female rats. Neurotoxicol Teratol 23: 665-673.
27. Lisboa SFS, Oliveira PE, Costa LC, Venancio EJ, Moreira EG 2007. Behavioral evaluation of male and female mice pups exposed to fluoxetine during pregnancy and lactation. Pharmacology 80: 49-56.
28. McKenna DJ 2004. Clinical investigations of the therapeutic potential of ayahuasca: rationale and regulatory challenges. Pharmacol Therapeut 102: 111-129.
29. Naseer MI, Shupeng L, Kim MO 2009. Maternal epileptic seizure induced by pentylenetetrazol: apoptotic neurodegeneration and decreased GABAB1 receptor expression in prenatal rat brain. Mol Brain Res 2: 20.
30. Norton S 1989. Methods for behavioral toxicology. In: Hayes A. Principles and methods of toxicology. 2 ed. New York: Raven; p. 553-571.
31. Oliveira CDR, Moreira CQ, De Sá LRM, Spinosa HS, Yonamine M 2010. Maternal and Developmental Toxicity of ayahuasca in Wistar Rats. Birth Defects Res B 89: 207-212.
32. Pellow S, Chopin P, File SE, Briley M 1985. Validation of open - closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Meth 14: 149-167.
33. Pires APS, De Oliveira CDR, Moura S, Dorr FA, Silva WAE, Yonamine M 2009. Gas Chromatographic Analysis of dimethyltryptamine and beta-carboline alkaloids in ayahuasca, an Amazonian psychoactive plant beverage. Phytochem Analysis 20: 149-153.
34. Porsolt RD, Lepichon M, Jalfre M 1997. Depression - new animal-model sensitive to antidepressant treatments. Nature 266: 730-732.
35. Prut L, Belzung C 2003. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol 463: 3-33.
36. Riba J, Barbanoj MJ 2005. Bringing ayahuasca to the clinical research laboratory. J Psychoactive Drugs 37: 219-230.
37. Riba J, Valle M, Urbano G, Yritia M, Morte A, Barbanoj MJ 2003. Human pharmacology of ayahuasca: subjective and cardiovascular effects, monoamine metabolite excretion, and pharmacokinetics. J Pharmacol Exp Ther 306: 73-83.
38. Schwarz A, Gornak SL, Bernardi MM, Dagli MLZ, Spinosa HS 2003. Effects of Ipomoea carnea aqueous fraction intake by dams during pregnancy on the physical and neurobehavioral development of rat offspring. Neurotoxicol Teratol 25: 615-626.
39. Setler P, Sarau H, McKenzie G 1976. Differential attenuation of some effects of haloperidol in rats given scopolamine. Eur J Pharmacol 39: 117-126.
40. Trezza V, Campolongo P, Cassano T, Macheda T, Dipasquale P, Carratu MR, Gaetani S, Cuomo, E 2008. Effects of perinatal exposure to delta-9-tetrahydrocannabinol on the emotional reactivity of the offspring: a longitudinal behavioral study in Wistar rats. Psychopharmacology 198: 529-537.
41. Tupper KW 2008. The globalization of ayahuasca: Harm reduction or benefit maximization? Int J Drug Policy 19: 297-303.
42. Zbinden G 1981. Experimental methods in behavioral teratology. Arch Toxicol 48: 69-88.